The decision may allow others to offer BRCA testing at lower cost. Jean A. Sachs, MSS, MLSP, Living Beyond Breast Cancer’s chief executive officer, and the LBBC staff want to know what you think about this ruling.
June 14, 2013 – PHILADELPHIA – The nine justices of the U.S. Supreme Court ruled unanimously yesterday in Association for Molecular Pathology v. Myriad Genetics that corporations may not patent human genes because they are products of nature.
“This decision has important implications for all women and families affected by hereditary breast cancer, potentially lowering the costs of genetic tests, increasing access to second opinions, and encouraging unfettered communication among researchers into the causes of disease,” said Jean A. Sachs, MSS, MLSP, CEO of Living Beyond Breast Cancer.
The case focused on Myriad Genetics’ patent claim over BRCA1 and BRCA2, genes that repair damage to cells in all humans. When mutated…
View original post 412 more words